Reg 32 non-applicability declaration for Q2 FY27

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.2%Reaction day

₹76.69

prior close

₹73.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%-2.9% vs market

Pharmaceuticals peers, median of 173sector-0.8%-3.4% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

+0.7

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.2-1.3-2.9-0.8-3.4

Next day

-4.8-1.3-3.5-1.2-3.6

-6.4+0.0-6.4-0.4-6.0

-6.4-0.2-6.2-0.1-6.3

-4.2-3.0-1.2-3.0-1.1

-4.6-2.7-1.8-3.1-1.4

-11.3-1.7-9.6-3.0-8.3

15d

-12.0-8.9-3.2-6.9-5.1

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Colinz Laboratories has informed BSE that SEBI LODR Regulation 32, which deals with reporting deviations or variations in use of proceeds from public, rights, preferential or QIP issues, is not applicable to the company for the quarter ended 30 September 2026. The company stated it has not undertaken any public issue, rights issue, preferential issue or QIP, so the regulation does not apply. Signed by Director Vijaya Mani.

Likely market impact

Routine compliance filing with no material impact on shareholders or the stock. Simply confirms no recent capital raise to report on.